Westminster, CA – January 29, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced the launching of a new subsidiary – BioLargo Equipment Solutions & Technologies, Inc. (BEST) – to capitalize on substantial opportunities for its technologies in the water treatment industry. BEST will enable BioLargo to represent all its water technologies under one roof, better support its sales and distribution network of qualified reps and channel partners, and will initially focus on:
- the AEC, an effective, sustainable, low-waste technology for removing per- and polyfluoroalkyl substances (PFAS) from water which is combined with a turnkey collection and destruction solution for customers;
- the AOS (Advanced Oxidation System), a technology targeted at energy-efficient water disinfection and micropollutant destruction;
- the AROS (Aqueous Reuse Optimization System), a water recycling technology for use in cooling towers and industrial wastewater that was developed in partnership with Garratt-Callahan;
- industrial odor control products under the CupriDyne brand offered by sister company ONM Environmental; and
- water treatment solutions developed by third party technology manufacturers for which BEST is an authorized reseller in order to provide complete solutions for its customers.
Tonya Chandler, BioLargo’s Director of Technical
Commercialization, has agreed to move into the role as president of the new subsidiary.
Tonya has over 20 years’ experience developing selling channels and managing
complex projects and accounts in the water industry and is ideally suited to
lead efforts to sell and monetize BioLargo’s water treatment technologies. She
also established herself as a recognized expert in PFAS water treatment invited
to speak at numerous conferences and educational, including continuing
education units for engineers, and similar events throughout the year and
continuing into 2024.
Although new to the role of president of BEST, Tonya has
been building a nationwide sales organization for BioLargo’s water treatment
technologies, and she led the efforts to establish BEST’s pipeline of potential
projects. The building of this pipeline has been demanding work. Each project goes
through a rigorous process to test water and identify a solution, which is
presented to the prospective client. At their request, proposed engagements
include proposed engineering, pricing, timing, supply chain support and
relationships, permitting, and customization as required. The pipeline continues
to expand.
Tonya commented, “The municipal drinking water project we
secured in New Jersey for a PFAS treatment system is just the start for BEST. As
our first opportunity to for field validation of our technology’s superior PFAS
removal performance and minimal waste generation, we believe it will open the
floodgates of client opportunities. We are working on commencing on-site pilots
for other target markets for our PFAS technology, including fire-fighting foam
remediation, ground water, wastewater and landfill leachate.”
CEO of BioLargo, Inc., Dennis P. Calvert commented, “It
isn’t easy to launch new and innovative technologies into the water industry, a
historically risk-averse market. Our strategy is to execute successful projects
with initial reference customers, create iron-clad case studies, then foster
recognition of our technologies in the industry with key opinion leaders. Tonya
is perfectly suited to lead this effort and we also are actively recruiting
additional team members to help us grow as we bring on and support additional
customers. We look forward to sharing more information as the business
progresses.”
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences
innovator and engineering services solution provider. Our core products address
PFAS contamination, achieve advanced water and wastewater treatment, control
odor and VOCs, improve air quality, enable energy-efficiency and safe on-site
energy storage, and control infections and infectious disease. Our approach is
to invent or acquire novel technologies, develop them into product offerings,
and extend their commercial reach through licensing and channel partnerships to
maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding anticipated revenue; and
plans for future operations. These statements involve risks and uncertainties,
and actual results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties include without
limitation: the effect of regional economic conditions on the Company’s
business, including effects on purchasing decisions by consumers and
businesses; the ability of the Company to compete in markets that are highly
competitive and subject to rapid technological change; the ability of the
Company to manage frequent introductions and transitions of products and
services, including delivering to the marketplace, and stimulating customer
demand for, new products, services, and technological innovations on a timely
basis; the dependency of the Company on the performance of distributors of the
Company’s products. More information on these risks and other potential factors
that could affect the Company’s business and financial results is included in
the Company’s filings with the SEC, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
